Echocardiography Guided TAVR (Echo TAVR)

Conventional transcatheter aortic valve replacement (TAVR) relies on fluoroscopic and contrast agents. However, in high-risk patients, exposure to ionizing radiation and contrast agents is contraindicated and undesirable. Echocardiography guidance TAVR can offer a feasible and safer strategy for TAVR.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Transcatheter Aortic Valve Replacemen Echocardiography

Sex eligibility

All sexes

Study type

Observational

Primary location

Fuwai Hospital

Beijing, 100037, China

Location status: Recruiting

Location contact

Xiangbin Pan, MD

CONTACT

[email protected]

88396655

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

symptomatic severe AS determined by echocardiography and Doppler that requiring aortic valve replacement, which is defined as: mean gradient ≥40 mmHg, peak aortic velocity ≥4 m/s, and aortic valve area (AVA) ≤1 cm2 (or an indexed AVA ≤0.6 cm2/m2);
a history of malignancy or a high familial risk of cancer, with refusal to undergo contrast- or radiation-guided procedures;
chronic kidney disease and refuse to receive contrast agents or radiation exposure.

Exclusion criteria

Required hybrid procedures or concomitant interventions on other cardiac malformations; Deemed inoperable due to extremely high surgical risk or severe comorbidities; Had untreated clinically significant coronary vascular disease amenable to revascularization; Previously undergone aortic valve replacement.

Treatment and study plan

Primary outcomes

Valve Academic Research Consortium-3 (VARC-3)

Time frame: 30-day after surgery

VARC3 include but not limited to Mortality (all-cause and cardiovascular) Stroke and transient ischemic attack (TIA) Acute kidney injury Conduction disturbances and permanent pacemaker implantation Bleeding (updated using BARC criteria) Myocardial infarction Vascular access complications Endocarditis

Study contacts

Contact information is provided by the study sponsor or research team.

Fengwen Zhang, MD

CONTACT

88396654

Xiangbin Pan, MD

CONTACT

[email protected]

88396655

Sponsors and collaborators

Lead sponsor

Pan Xiangbin

Other

Registry information

Official study title

Transcatheter Aortic Valve Replacement With Echocardiography Guidance

Important dates

Study start: 2025
Primary completion: 2025
Study completion: 2025
First posted: Jun 19, 2025
Registry last updated: Jun 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed